Inactivation of the viral interleukin 1β receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara

Journal of General Virology

Volumn 86, Issue 7, 2005, Pages 1997-2006

  Staib, Caroline ^a   Kisling, Sigrid ^a   Erfle, Volker ^a   Sutter, Gerd ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; HLA A ANTIGEN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA RECEPTOR; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS ANTIGEN;

ACUTE PHASE RESPONSE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FEVER; GENE DELETION; GENE INSERTION; GENE SEQUENCE; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNIZATION; INFECTION RESISTANCE; INFLAMMATION; MARKER GENE; MEMORY CELL; MODULATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGENY; REGULATORY MECHANISM; RESPIRATORY TRACT INFECTION; STRAIN DIFFERENCE; T LYMPHOCYTE; TISSUE CULTURE; TRANSGENIC MOUSE; VACCINIA; VACCINIA VIRUS; VIRUS IMMUNITY; VIRUS MUTANT; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENE DELETION; IMMUNIZATION; IMMUNOLOGIC MEMORY; INTERLEUKIN-1; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, INTERLEUKIN; RECEPTORS, VIRUS; VACCINIA; VACCINIA VIRUS; VIRAL VACCINES;

ANKARA; MUS MUSCULUS; VACCINIA VIRUS;

EID: 21444435368     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.80646-0     Document Type: Article

References (47)

1. Alcami, A. (2003). Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol 3, 36-50.
2. Alcami, A. & Smith, G. (1992). A soluble receptor for interleukin-1β encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71, 153-167.
3. Alcami, A. & Smith, G. L. (1996). A mechanism for the inhibition of fever by a virus. Proc Natl Acad Sci U S A 93, 11029-11034.
4. Amara, R. R., Nigam, P., Sharma, S., Liu, J. & Bostik, V. (2004). Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol 78, 3811-3816.
5. Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. (1998). The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365-396.
6. Belyakov, I. M., Earl, P., Dzutsev, A. & 8 other authors (2003). Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A 100, 9458-9463.
7. Blanchard, T. J., Alcami, A., Andrea, P. & Smith, G. L. (1998). Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79, 1159-1167.
8. Carroll, M. W. & Moss, B. (1997). Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238, 198-211.
9. Corona Gutierrez, C. M., Tinoco, A., Lopez Contreras, M., Navarro, T., Calzado, P., Vargas, L., Reyes, L., Posternak, R. & Rosales, R. (2002). Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. Hum Gene Ther 13, 1127-1140.
10. Cosma, A., Nagaraj, R., Buhler, S., Hinkula, J., Busch, D. H., Sutter, G., Goebel, F. D. & Erfle, V. (2003). Therapeutic vaccination with MVA-HIV-1 nef elicits nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22, 21-29.
11. + cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial. Hum Gene Ther 14, 1347-1360.
12. Drexler, I., Heller, K., Wahren, B., Erfle, V. & Sutter, G. (1998). Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79, 347-352.
13. Drexler, I., Staib, C., Kastenmuller, W. & 8 other authors (2003). Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A 100, 217-222.
14. Earl, P. L., Americo, J. L., Wyatt, L. S. & 15 other authors (2004). Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428, 182-185.
15. + T cell polarization in mice is modulated by strain-specific major histocompatibility complex-independent differences within dendritic cells. J Exp Med 198, 201-209.
16. Guo, Z., Zhang, M., An, H., Chen, W., Liu, S., Guo, J., Yu, Y. & Cao, X. (2003). Fas ligation induces IL-1β-dependent maturation and IL-1β-independent survival of dendritic cells: different roles of ERK and NF-κB signaling pathways. Blood 102, 4441-4447.
17. Hornemann, S., Harlin, O., Staib, C., Kisling, S., Erfle, V., Kaspers, B., Hacker, G. & Sutter, G. (2003). Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. J Virol 77, 8394-8407.
18. + T cell activation in vivo: with help from interleukin 1. J Exp Med 198, 185-190.
19. + T cells. Proc Natl Acad Sci U S A 99, 6198-6203.
20. Mayr, A. & Munz, E. (1964). Veränderungen von Vaccinevirus durch Dauerpassagen in Hühnerfibroblastenkulturen. Zentralbl Bakteriol [Orig] 195, 24.
21. Mayr, A., Hochstein-Mintzel, V. & Stickl, H. (1975). Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 3, 6-14.
22. Mayr, A., Stickl, H., Müller, H., Danner, K. & Singer, H. (1978). Der Pockenimpfstamm MVA: Marker, genetische Struktur, Erfahrungen mit der parenteralen Schutzimpfung und Verhalten im abwehrgeschwächten Organismus. Zentralbl Bakteriol [Orig B] 167, 375-390.
23. McConkey, S. J., Reece, W. H., Moorthy, V. S. & 25 other authors (2003). Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9, 729-735.
24. Meyer, H., Sutter, G. & Mayr, A. (1991). Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72, 1031-1038.
25. Moss, B. & Earl, P. L. (1991). Preparation of cell cultures and vaccinia virus stocks. In Current Protocols in Molecular Biology, pp. 16.16.11-16.16.17. Edited by F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith & K. Struhl. New York: Wiley & Sons.
26. Moss, B. & Shisler, J. L. (2001). Immunology 101 at poxvirus U: immune evasion genes. Semin Immunol 13, 59-66.
27. Moss, B., Carroll, M. W., Wyatt, L. S. & 12 other authors (1996). Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 397, 7-13.
28. b β2m double knockout mice. J Exp Med 185, 2043-2051.
29. Ramirez, J. C., Gherardi, M. M. & Esteban, M. (2000). Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74, 923-933.
30. Reading, P. C. & Smith, G. L. (2003a). Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J Virol 77, 9960-9968.
31. Reading, P. C. & Smith, G. L. (2003b). A kinetic analysis of immune mediators in the lungs of mice infected with vaccinia virus and comparison with intradermal infection. J Gen Virol 84, 1973-1983.
32. Reading, P. C., Moore, J. B. & Smith, G. L. (2003). Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection. J Exp Med 197, 1269-1278.
33. Rochlitz, C., Figlin, R., Squiban, P. & 8 other authors (2003). Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 5, 690-699.
34. Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). Molecular Cloning: a Laboratory Manual, 2nd edn. Cold Spring Harbor: NY: Cold Spring Harbor Laboratory.
35. Santra, S., Barouch, D. H., Korioth-Schmitz, B. & 18 other authors (2004). Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc Natl Acad Sci U S A 101, 11088-11093.
36. Sims, J. E. (2002). IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol 14, 117-122.
37. Spriggs, M., Hruby, D., Maliszewski, C., Pickup, D., Sims, J., Buller, R. M. & VanSlyke, J. (1992). Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell 71, 145-152.
38. Staib, C. & Sutter, G. (2003). Live viral vectors: vaccinia virus. Methods Mol Med 87, 51-68.
39. Staib, C., Drexler, I., Ohlmann, M., Wintersperger, S., Erfle, V. & Sutter, G. (2000). Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques 28, 1137-1142, 1144-1146, 1148.
40. Staib, C., Lowel, M., Erfle, V. & Sutter, G. (2003). Improved host range selection for recombinant modified vaccinia virus Ankara. Biotechniques 34, 694-696, 698, 700.
41. Stickl, H., Hochstein-Mintzel, V., Mayr, A., Huber, H., Schäfer, H. & Holzner, A. (1974). MVA-Stufenimpfung gegen Pocken. Dtsch Med Wochenschr 99, 2386-2392.
42. Stittelaar, K. J., Kuiken, T., de Swart, R. L. & 8 other authors (2001). Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19, 3700-3709.
43. Sutter, G. & Moss, B. (1992). Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 89, 10847-10851.
44. Sutter, G. & Moss, B. (1995). Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev Biol Stand 84, 195-200.
45. 1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB /c mice. J Exp Med 198, 191-199.
46. Williamson, J. D., Reith, R. W., Jeffrey, L. J., Arrand, J. R. & Mackett, M. (1990). Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol 71, 2761-2767.
47. Wyatt, L. S., Earl, P. L., Eller, L. A. & Moss, B. (2004). Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A 101, 4590-4595.